UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science)

UPWARDS 培训计划(代表性不足的少数族裔致力于科学研究多样性)

基本信息

  • 批准号:
    10252909
  • 负责人:
  • 金额:
    $ 43.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-03 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT As a recognized leader in cancer research,1 MD Anderson Cancer Center is well poised to address a significant lack of diversity in the cancer research workforce that contributes to considerable disparities.2-6 We will do so via early intervention programs that foster sustained interest in cancer research in students underrepresented and minority in Science (URMS). Since 2011, we have directed a summer undergraduate training program encompassing 345 trainees (from 2011-2018), including 120 URMS. Significantly, outcomes for URMS and non-minority trainees in our program are indistinguishable; URMS and non-minority alumni are enrolled in or have completed STEM bachelor’s (98.8% vs 98.1%) and doctoral (both 67.1%) degrees and are retained in STEM education or workforce (98.3% vs 98.6%, respectively). Built upon these successes, we have designed a comprehensive cancer research training program for high school and undergraduate URMS via the R25 YES initiative. In our URMS-focused program, we address major barriers in URMS pursuit and success in STEM, including: limited 1) research experience, 2) career path knowledge, and 3) scientific identity formation and exposure to science; 4) underdeveloped professionalism and communication skills; 5) inadequate research, educational, and career mentoring; and 6) barriers in the graduate application process. Our proposed UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science) has 3 tracks: full-time, 12-week summer research for 1) high-schoolers and 2) undergraduates and 3) part-time, 40-week research for undergraduates. Within each track, we propose the following aims to address the aforementioned barriers: Aim 1) Employ focused URMS recruitment and holistic strategies for program inclusion, and deliver didactic learning and hands-on cancer research experiences through a cadre of outstanding mentoring faculty. Aim 2) Develop and deliver individualized mentoring, career exploration, and professional development that stimulates graduate education and cancer research career pursuit. Aim 3) Educate and inspire URMS communities, young generations in the STEM pipeline, and the families and support systems of our students through training, STEM outreach, and hands-on engagement. We will encourage our trainees to lead and encourage their communities and younger generations through hands-on STEM outreach activities and design and delivery of community education. Aim 4) Implement and maintain a rigorous assessment program with continual appraisal and enactment of novel, evidence-driven best practices derived from these efforts. Lastly, we commit to disseminating our findings and best practices via peer-reviewed publications. Through the UPWARDS Program, we will build upon our prior experiences and best practices to launch a cancer research training program specifically designed to fit the needs of URMS trainees in our local community and nationally. We anticipate our efforts will effectively increase diversity in the STEM educational pipeline and cancer research workforce.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KHANDAN KEYOMARSI其他文献

KHANDAN KEYOMARSI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KHANDAN KEYOMARSI', 18)}}的其他基金

Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
靶向 STAT3 治疗 CDK4/6 抑制剂耐药的晚期雌激素受体阳性乳腺癌患者
  • 批准号:
    10316167
  • 财政年份:
    2020
  • 资助金额:
    $ 43.04万
  • 项目类别:
UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science)
UPWARDS 培训计划(代表性不足的少数族裔致力于科学研究多样性)
  • 批准号:
    10023785
  • 财政年份:
    2020
  • 资助金额:
    $ 43.04万
  • 项目类别:
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
靶向 STAT3 治疗 CDK4/6 抑制剂耐药的晚期雌激素受体阳性乳腺癌患者
  • 批准号:
    10097489
  • 财政年份:
    2020
  • 资助金额:
    $ 43.04万
  • 项目类别:
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer
细胞质周期蛋白 E 是进展为浸润性乳腺癌的早期事件
  • 批准号:
    10550153
  • 财政年份:
    2018
  • 资助金额:
    $ 43.04万
  • 项目类别:
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer
细胞质周期蛋白 E 是进展为浸润性乳腺癌的早期事件
  • 批准号:
    9436336
  • 财政年份:
    2018
  • 资助金额:
    $ 43.04万
  • 项目类别:
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer
细胞质周期蛋白 E 是进展为浸润性乳腺癌的早期事件
  • 批准号:
    10337331
  • 财政年份:
    2018
  • 资助金额:
    $ 43.04万
  • 项目类别:
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer
细胞质周期蛋白 E 是进展为浸润性乳腺癌的早期事件
  • 批准号:
    10113558
  • 财政年份:
    2018
  • 资助金额:
    $ 43.04万
  • 项目类别:
Targeting the cell cycle in triple negative breast cancer
靶向三阴性乳腺癌的细胞周期
  • 批准号:
    8250334
  • 财政年份:
    2011
  • 资助金额:
    $ 43.04万
  • 项目类别:
Targeting the cell cycle in triple negative breast cancer
靶向三阴性乳腺癌的细胞周期
  • 批准号:
    8631060
  • 财政年份:
    2011
  • 资助金额:
    $ 43.04万
  • 项目类别:
Targeting the cell cycle in triple negative breast cancer
靶向三阴性乳腺癌的细胞周期
  • 批准号:
    8454512
  • 财政年份:
    2011
  • 资助金额:
    $ 43.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了